Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

Hepatology Research

Volumn 40, Issue 1, 2010, Pages 1-7

  Kumada, Hiromitsu ^a   Okanoue, Takeshi ^b   Onji, Morikazu ^c   Moriwaki, Hisataka ^d   Izumi, Namiki ^e   Tanaka, Eiji ^f   Chayama, Kazuaki ^g   Sakisaka, Shotaro ^h   Takehara, Tetsuo ⁱ   Oketani, Makoto ^j   Suzuki, Fumitaka ^a   Toyota, Joji ^k   Nomura, Hideyuki ^l   Yoshioka, Kentaro ^m   Seike, Masataka ⁿ   Yotsuyanagi, Hiroshi ^o   Ueno, Yoshiyuki ^p  

^a TORANOMON HOSPITAL   (Japan)

^b Saiseikai Suita Hospital   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e MUSASHINO RED CROSS HOSPITAL   (Japan)

^f SHINSHU UNIVERSITY   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

^j Health Research Human and Environmental Science   (Japan)

^k 5 N3E8   (Japan)

^l Shin Kokura Hospital   (Japan)

^m FUJITA HEALTH UNIVERSITY   (Japan)

ⁿ OITA UNIVERSITY   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

^p TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chronic hepatitis; Cirrhosis; Hepatitis B virus; Hepatocellular carcinoma; Interferon; Liver supportive therapies; Nucleos(t)ide analogs

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BRANCHED CHAIN AMINO ACID; ENTECAVIR; GLYCYRRHIZIC ACID; HEPATITIS E ANTIGEN; INTERFERON; LAMIVUDINE; LIVACT; NEOMINOPHAGEN C; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CANCER RISK; DECOMPENSATED LIVER CIRRHOSIS; DIET SUPPLEMENTATION; GENOTYPE; GROUPS BY AGE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INDICATION; VIRUS LOAD; VIRUS MUTANT; VIRUS RESISTANCE;

EID: 77954409307     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00633.x     Document Type: Review

References (11)

1. Serfaty L, Thabut D, Zoulim F. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001, 34:573-7.
2. Shindo M, Chayama K, Mochida S. Antiviral activity,dose-responce relationship, and safety of entecavir following 24 week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009
3. Kobayashi H, Fujioka S, Kawaguchi MK. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009, 3:403-10.
4. Suzuki F, Toyoda J, Katano Y. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008, 23:1320-6.
5. Shakado S, Watanabe H, Tanaka T. Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B. Hepatol Int 2009, 2:361-9.
6. Akuta N, Suzuki F, Kawamura Y. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. Intervirology 2008, 51:385-93.
7. Hosaka T, Suzuki F, Suzuki Y. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007, 42:368-74.
8. Yatsuji H, Suzuki F, Sezaki H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008, 48:923-31.
9. Arase Y, Ikeda K, Murashima N. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79:1494-500.
10. Omata M, Yoshida H, Toyota J. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007, 56:1747-53.
11. Muto Y, Sato S, Watanabe A. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-14.